Lv72
4980 积分 2022-08-11 加入
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
6小时前
已完结
OA08.01 BMS-986504 in Patients With Homozygous MTAP-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007
11小时前
求助中
P3.18.71 CA240-0007: BMS-986504 With Anti-PD-1 or Chemotherapy as Treatment for Advanced Solid Tumors With Homozygous MTAP Deletion
11小时前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
1天前
已完结
How AI agents will change research: a scientist’s guide
3天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
26天前
已完结
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates anti-tumor activity in metastatic castration-resistant prostate cancer
26天前
已完结
[Research Advance on the Role of Spleen Tyrosine Kinase Inhibitors in Hematologic Malignancies]
28天前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
1个月前
已完结
DDIS-22. WSD0922: A BBB PENETRABLE EGFR/EGFRVIII SMALL MOLECULE FOR THE TREATMENT OF GBM AND METASTATIC CNS TUMOR
1个月前
已完结
皖公网安备34019202002308
